Literature DB >> 12084531

Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences.

Paul A Rushing1, Randy J Seeley, Ellen L Air, Thomas A Lutz, Stephen C Woods.   

Abstract

In this study, a conditioned taste aversion (CTA) paradigm was used to assess the possibility that 3rd-ventricular (i3vt) administration of the pancreatic hormone amylin produces aversive consequences that secondarily reduce food intake independently of the normal regulation of energy balance. After 1-h daily access to water for 7 days, rats were given 1-h access to a 0.15% saccharin solution, followed immediately by i3vt amylin (100 pmol) in one group (n=7) and i3vt CSF vehicle in another (n=7). As positive control for the formation of a CTA, a third group of seven rats received intraperitonial (i.p.) lithium chloride (LiCl). Saline was given i.p. to a fourth group (n=7) as control for i.p. LiCl. As expected, the LiCl rats exhibited a marked aversion to the saccharin in a subsequent two-bottle intake test. In contrast, although the 100 pmol i3vt amylin dose is substantially higher than that required to reduce food intake, no evidence of a CTA was observed in the rats that had received i3vt amylin. In summary, these data are consistent with the conclusion that acute i3vt amylin infusion does not reduce food intake by producing aversive consequences.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084531     DOI: 10.1016/s0196-9781(02)00022-0

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  13 in total

Review 1.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 2.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 3.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  Amylin-mediated control of glycemia, energy balance, and cognition.

Authors:  Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2016-02-27

5.  A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference.

Authors:  Sofie Gydesen; Sara Toftegaard Hjuler; Zenia Freving; Kim Vietz Andreassen; Nina Sonne; Lars I Hellgren; Morten Asser Karsdal; Kim Henriksen
Journal:  Br J Pharmacol       Date:  2017-02-15       Impact factor: 8.739

Review 6.  Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure.

Authors:  T A Lutz
Journal:  Int J Obes Suppl       Date:  2016-11-16

7.  Central amylin acts as an adiposity signal to control body weight and energy expenditure.

Authors:  Peter Y Wielinga; Christian Löwenstein; Sabine Muff; Manuela Munz; Stephen C Woods; Thomas A Lutz
Journal:  Physiol Behav       Date:  2010-04-21

8.  Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity.

Authors:  Ambrose A Dunn-Meynell; Christelle Le Foll; Miranda D Johnson; Thomas A Lutz; Matthew R Hayes; Barry E Levin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-12-16       Impact factor: 3.619

9.  Fluid intake, what's dopamine got to do with it?

Authors:  Elizabeth G Mietlicki-Baase; Jessica Santollo; Derek Daniels
Journal:  Physiol Behav       Date:  2021-04-07

10.  The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats.

Authors:  Lauren M Stein; Lauren E McGrath; Rinzin Lhamo; Kieran Koch-Laskowski; Samantha M Fortin; Jolanta Skarbaliene; Tamara Baader-Pagler; Rasmus Just; Matthew R Hayes; Elizabeth G Mietlicki-Baase
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-07-14       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.